Published in FEBS Lett on February 27, 2003
Asymmetric segregation of protein aggregates is associated with cellular aging and rejuvenation. Proc Natl Acad Sci U S A (2008) 3.56
Monitoring protein stability and aggregation in vivo by real-time fluorescent labeling. Proc Natl Acad Sci U S A (2003) 2.43
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Characterization of the aggregates formed during recombinant protein expression in bacteria. BMC Biochem (2005) 1.38
Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. J Bacteriol (2005) 1.12
Sequence determinants of protein aggregation: tools to increase protein solubility. Microb Cell Fact (2005) 1.09
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
The small heat-shock proteins IbpA and IbpB reduce the stress load of recombinant Escherichia coli and delay degradation of inclusion bodies. Microb Cell Fact (2005) 1.02
Towards revealing the structure of bacterial inclusion bodies. Prion (2009) 0.97
The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microb Cell Fact (2006) 0.95
Effects of SecE depletion on the inner and outer membrane proteomes of Escherichia coli. J Bacteriol (2008) 0.94
How to achieve high-level expression of microbial enzymes: strategies and perspectives. Bioengineered (2013) 0.91
Quality control of inclusion bodies in Escherichia coli. Microb Cell Fact (2010) 0.90
Cell factories for insulin production. Microb Cell Fact (2014) 0.88
Production of recombinant proteins in the lon-deficient BL21(DE3) strain of Escherichia coli in the absence of the DnaK chaperone. Appl Environ Microbiol (2009) 0.88
Variation in the Subcellular Localization and Protein Folding Activity among Arabidopsis thaliana Homologs of Protein Disulfide Isomerase. Biomolecules (2013) 0.78
Expression and fermentation optimization of oxidized polyvinyl alcohol hydrolase in E. coli. J Ind Microbiol Biotechnol (2011) 0.78
Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. Microb Cell Fact (2011) 0.77
Chaperone-Assisted Soluble Expression of a Humanized Anti-EGFR ScFv Antibody in E. Coli. Adv Pharm Bull (2015) 0.75
Protein quality in bacterial inclusion bodies. Trends Biotechnol (2006) 2.02
Amyloid-like properties of bacterial inclusion bodies. J Mol Biol (2005) 1.90
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact (2005) 1.79
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact (2009) 1.59
The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng (2007) 1.34
Recombinant protein solubility - does more mean better? Nat Biotechnol (2007) 1.21
Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol (2006) 1.20
Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol (2007) 1.18
Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. J Bacteriol (2005) 1.12
Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact (2010) 1.09
Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact (2009) 1.09
Biomedical applications of distally controlled magnetic nanoparticles. Trends Biotechnol (2009) 1.08
Bacterial inclusion bodies: making gold from waste. Trends Biotechnol (2011) 1.07
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnol Adv (2012) 1.05
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J (2011) 1.01
Folding of a misfolding-prone beta-galactosidase in absence of DnaK. Biotechnol Bioeng (2005) 1.01
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology (2010) 1.00
Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. Biotechnol Bioeng (2008) 0.99
Nanostructured bacterial materials for innovative medicines. Trends Microbiol (2010) 0.95
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microb Cell Fact (2006) 0.95
The Functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol (2008) 0.94
Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol (2008) 0.91
Systems metabolic engineering, industrial biotechnology and microbial cell factories. Microb Cell Fact (2012) 0.90
The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials (2010) 0.90
Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol (2011) 0.89
Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater (2012) 0.89
Modular protein engineering for non-viral gene therapy. Trends Biotechnol (2004) 0.88
Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. J Biotechnol (2005) 0.87
Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies. Biochem Biophys Res Commun (2007) 0.87
Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) (2010) 0.87
Insertional protein engineering for analytical molecular sensing. Microb Cell Fact (2006) 0.87
Influence of growth temperature on the production of antibody Fab fragments in different microbes: a host comparative analysis. Biotechnol Prog (2010) 0.86
Modular protein engineering in emerging cancer therapies. Curr Pharm Des (2009) 0.86
Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnol Adv (2009) 0.86
Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-forming Escherichia coli cells. FEMS Microbiol Lett (2007) 0.86
Production of functional inclusion bodies in endotoxin-free Escherichia coli. Appl Microbiol Biotechnol (2014) 0.85
Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. Biochem Biophys Res Commun (2004) 0.85
Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol (2009) 0.84
Post-production protein stability: trouble beyond the cell factory. Microb Cell Fact (2011) 0.84
Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact (2011) 0.83
Lon and ClpP proteases participate in the physiological disintegration of bacterial inclusion bodies. J Biotechnol (2005) 0.83
Fast electrochemical detection of anti-HIV antibodies: coupling allosteric enzymes and disk microelectrode arrays. Anal Chim Acta (2009) 0.83
Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials (2010) 0.83
In situ protein folding and activation in bacterial inclusion bodies. Biotechnol Bioeng (2008) 0.83
Recombinant protein quality evaluation: proposal for a minimal information standard. Stand Genomic Sci (2011) 0.82
Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. Nanomedicine (Lond) (2015) 0.82
Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. Appl Microbiol Biotechnol (2015) 0.81
Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors. Biochim Biophys Acta (2002) 0.81
Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochem Biophys Res Commun (2003) 0.81
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine (2012) 0.81
Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today (2008) 0.81
DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. Appl Microbiol Biotechnol (2009) 0.80
Interleukin-10 overexpression does not synergize with the neuroprotective action of RGD-containing vectors after postnatal brain excitotoxicity but modulates the main inflammatory cell responses. J Neurosci Res (2011) 0.80
The impact of dnaKJ overexpression on recombinant protein solubility results from antagonistic effects on the control of protein quality. Biotechnol Lett (2004) 0.80
Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomater (2012) 0.80
Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond. Nanomedicine (Lond) (2013) 0.79
Cellular uptake and intracellular fate of protein releasing bacterial amyloids in mammalian cells. Soft Matter (2016) 0.79
Analytical approaches for assessing aggregation of protein biopharmaceuticals. Curr Pharm Biotechnol (2011) 0.79
High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. Mol Immunol (2006) 0.79
Control of Escherichia coli growth rate through cell density. Microbiol Res (2002) 0.79
Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering. Nanomedicine (Lond) (2011) 0.79
A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs. Nanomedicine (Lond) (2013) 0.79
Nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions. Nanomedicine (Lond) (2011) 0.79
Bacterial inclusion bodies: an emerging platform for drug delivery and cell therapy. Nanomedicine (Lond) (2012) 0.78
Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay. J Biomol Screen (2010) 0.78
Overexpression of the nuclear factor kappaB inhibitor A20 is neurotoxic after an excitotoxic injury to the immature rat brain. Neurol Res (2012) 0.78
In vivo architectonic stability of fully de novo designed protein-only nanoparticles. ACS Nano (2014) 0.78
Topographically targeted osteogenesis of mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces. Nanomedicine (Lond) (2013) 0.78
RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine (2012) 0.78
Antiretroviral therapy-induced functional modification of IgG4 and IgM responses in HIV-1-infected individuals screened by an allosteric biosensor. J Biomol Screen (2008) 0.77
Disulfide bond formation and activation of Escherichia coli β-galactosidase under oxidizing conditions. Appl Environ Microbiol (2012) 0.77
Engineering of Escherichia coli beta-galactosidase for solvent display of a functional scFv antibody fragment. FEBS Lett (2003) 0.77
Discriminating foot-and-mouth disease virus-infected and vaccinated animals by use of beta-galactosidase allosteric biosensors. Clin Vaccine Immunol (2009) 0.77
Two-dimensional microscale engineering of protein-based nanoparticles for cell guidance. ACS Nano (2013) 0.77
Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials (2012) 0.77
Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. Microb Cell Fact (2011) 0.77
Engineering the E. coli beta-galactosidase for the screening of antiviral protease inhibitors. Biochem Biophys Res Commun (2005) 0.76
Recombinant protein materials for bioengineering and nanomedicine. Nanomedicine (Lond) (2014) 0.76
Bacterial inclusion body purification. Methods Mol Biol (2015) 0.76
Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. Crit Rev Biotechnol (2013) 0.76
Inclusion bodies of fuculose-1-phosphate aldolase as stable and reusable biocatalysts. Biotechnol Prog (2012) 0.76
Functionalization of 3D scaffolds with protein-releasing biomaterials for intracellular delivery. J Control Release (2013) 0.76
How to break recombinant bacteria: does it matter? Bioeng Bugs (2011) 0.76
Enhanced molecular recognition signal in allosteric biosensing by proper substrate selection. Biotechnol Bioeng (2006) 0.76
A novel bio-functional material based on mammalian cell aggresomes. Appl Microbiol Biotechnol (2015) 0.76
Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication (2016) 0.76
Screening HIV-1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors. J Mol Recognit (2009) 0.76
Engineering tumor cell targeting in nanoscale amyloidal materials. Nanotechnology (2016) 0.75
The scientific impact of microbial cell factories. Microb Cell Fact (2008) 0.75
Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. Dis Model Mech (2014) 0.75
Cross-system excision of chaperone-mediated proteolysis in chaperone-assisted recombinant protein production. Bioeng Bugs (2009) 0.75
Improved performance of protein-based recombinant gene therapy vehicles by tuning downstream procedures. Biotechnol Prog (2013) 0.75
Multifunctional nanovesicle-bioactive conjugates prepared by a one-step scalable method using CO2-expanded solvents. Nano Lett (2013) 0.75
Connection between gene dosage and protein stability revealed by a high-yield production of recombinant proteins in an E. coli LexA1(Ind-) background. Biotechnol Bioeng (2002) 0.75
Integrated approach to produce a recombinant, His-tagged human α-galactosidase A in mammalian cells. Biotechnol Prog (2011) 0.75
Engineering multifunctional protein nanoparticles by in vitro disassembling and reassembling of heterologous building blocks. Nanotechnology (2017) 0.75